cm512

Small moleculeexperimental

Clinical trial activity

7 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
6
Phase 3
0
Phase 4
0

Earliest trial started Sep 30, 2024 (NCT06553209)

Timeline

2020s

  1. Jan 1, 2024

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2025

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07230483Phase 2Dec 31, 2025Keymed Biosciences Co.Ltd, Peking University
NCT07166211Phase 2Sep 15, 2025Keymed Biosciences Co.Ltd
NCT07011524Phase 2Aug 19, 2025Keymed Biosciences Co.Ltd
NCT06980142Phase 2Jun 20, 2025Fudan University, Keymed Biosciences Co.Ltd
NCT06947980Phase 2Jun 19, 2025Keymed Biosciences Co.Ltd, Peking University
NCT06930612Phase 2May 16, 2025Capital Medical University, Keymed Biosciences Co.Ltd
NCT06553209Phase 1Sep 30, 2024Keymed Biosciences Co.Ltd, Sichuan University
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Keymed Biosciences Co.LtdFor profit7722024
Peking UniversityAcademic/Hospital2012025
Capital Medical UniversityAcademic/Hospital1012025
Fudan UniversityAcademic/Hospital1012025
Sichuan UniversityAcademic/Hospital1012024
5 organizations
Page 1 / 1